stockrowVistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025.
- Revenue
- +504.9%
- EPS
- +36.2%
- Free cash flow
- +22.2%
Quarter to June 2026, against a year earlier
Follow VTGN
Alert me
VistaGen Therapeutics, Inc. (VTGN) EV/Sales
As of 5 November 2026, VistaGen Therapeutics, Inc. (VTGN) trades at a EV/Sales of −6.4×. Over the past ten years it has ranged from −262× (August 2023) to 394× (July 2021); the current reading is higher than 15% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | −12.1× | — |
| FY2025 | 10.3× | (79.89%) |
| FY2024 | 51.4× | — |
| FY2023 | −78.0× | — |
| FY2022 | 170× | 332.40% |
| FY2021 | 39.3× | 274.58% |
| FY2017 | 10.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −5.4× | — |
| Mar 2026 | −12.1× | — |
| Dec 2025 | −32.4× | — |
| Sep 2025 | 80.5× | 478.42% |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. | −6.4× |
| SNGX Soligenix Inc. compare | −4.1× |
| MTVA MetaVia Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | 6.1× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 26.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)